Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors

NCT07623369 is registered in ClinicalTrials.gov with Huahui Health as lead sponsor.

NCT NCT07623369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07623369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Preliminary Antitumor Activity of HH160 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
Huahui Health
Phase
Phase 1
Overall status
Recruiting
Start date
June 11, 2026
Completion date
August 31, 2028
Enrollment
299 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colorectal cancer, endometrial cancer, gastroesophageal adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, renal cell carcinoma, small-cell lung cancer, solid tumor, triple negative breast cancer, urothelial carcinoma